Harrow demonstrated strong revenue growth and cash flow, along with successful strategic initiatives in product launches and market access. However, the quarter was marred by seasonal revenue weakness and significant one-time expenses. The company's outlook remains positive with expectations for growth in the remainder of the year.

Company Guidance -

Q2 2025

During Harrow's First Quarter 2025 Earnings Conference Call, the company provided guidance indicating a strong outlook for the remainder of the year. They aim to achieve their 2025 revenue target of over $280 million, requiring approximately $232 million in revenue across the next three quarters. In Q1 2025, Harrow's revenue grew by 38% year-over-year, with standout performance from VEVYE, which saw a 35% sequential revenue increase to $21.5 million. Harrow anticipates VEVYE will generate at least $100 million in revenue by year-end. IHEEZO is expected to deliver over $50 million, and the specialty branded products, including TRIESENCE, are projected to contribute at least $50 million. The ImprimisRx compounding business is on track to deliver more than $80 million. Harrow also reported a record $19.7 million in cash flow from operations in Q1 and discussed strategic initiatives such as the VEVYE Access for All program, which has quadrupled new prescriptions and prescribers within seven weeks of launch.

Significant Revenue Growth

Harrow reported a 38% year-over-year revenue growth in the first quarter of 2025.

Record Cash Flow

The company delivered a record $19.7 million in cash flow from operations.

VEVYE Revenue Increase

VEVYE revenue rose 35% sequentially, from $16 million in Q4 2024 to $21.5 million in Q1 2025.

Successful Launch of VEVYE Access for All Program

Post-launch, both new prescriptions and weekly VEVYE prescribers at PhilRx quadrupled.

Infrastructure Expansion

The VEVYE team has grown to over 80 sales and marketing professionals, with additional expansion in other teams.

Positive Market Response for TRIESENCE

Market access initiatives for TRIESENCE are expected to unlock about 40% of the overall market, showing significant sales momentum.

Strong ImprimisRx Performance

April appears to be a record month for ImprimisRx, indicating consistent performance.

Harrow Health (HROW) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HROW Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 11, 2025	2025 (Q2)	<0.01 / -	-0.18	―	―	―
May 08, 2025	2025 (Q1)	-0.05 / -0.50	-0.38	-31.58% (-0.12)
Mar 27, 2025	2024 (Q4)	0.08 / 0.24	-0.26	192.31% (+0.50)
Nov 13, 2024	2024 (Q3)	-0.05 / -0.12	-0.13	7.69% (+0.01)
Aug 07, 2024	2024 (Q2)	-0.18 / -0.18	-0.14	-28.57% (-0.04)
May 13, 2024	2024 (Q1)	-0.22 / -0.38	-0.22	-72.73% (-0.16)
Mar 19, 2024	2023 (Q4)	-0.04 / -0.26	0.04	-750.00% (-0.30)
Nov 13, 2023	2023 (Q3)	0.04 / -0.13	-0.24	45.83% (+0.11)
Aug 09, 2023	2023 (Q2)	-0.04 / -0.14	-0.23	39.13% (+0.09)
May 11, 2023	2023 (Q1)	-0.05 / -0.22	-0.09	-144.44% (-0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HROW Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$23.59	$24.40	+3.43%
Mar 27, 2025	$27.87	$26.21	-5.96%
Nov 13, 2024	$51.80	$42.86	-17.26%
Aug 07, 2024	$21.98	$33.92	+54.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.